> ## Content Index
> Fetch the complete content index at: https://www.sanarelab.science/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mebendazole Suppresses Colorectal Tumors with Low PNLDC1 Levels, Preclinical Study Finds
- URL: https://www.sanarelab.science/mebendazole-pnldc1-tubb4b-colorectal-cancer-2026/
- Published: 2026-09-24T08:14:07.000Z
- Updated: 2026-09-24T08:14:07.000Z
- Description: Preclinical work links low PNLDC1 expression to aggressive colorectal cancer growth via TUBB4B — and shows the antiparasitic mebendazole, a TUBB4B inhibitor, suppressing that growth in cells, xenografts and patient-derived tumor clusters.
- Author: Sanare Lab
- Tags: #short-read, News, Research, mebendazole

Key Takeaway

Colorectal tumors with low levels of the enzyme PNLDC1 grow more aggressively, and a new preclinical study shows the antiparasitic **mebendazole** — acting as a TUBB4B inhibitor — suppressing that excess growth in cancer cells, mouse xenografts and patient-derived tumor clusters. Bench evidence only; no patients were treated.

A team led by Lexin Liu reported in *Exploration* (September 21, 2026) that PNLDC1, a deadenylase enzyme sitting in the endoplasmic reticulum, is under-expressed in an analysis of 91 clinical colorectal cancer (CRC) tissue samples. Functional experiments identified PNLDC1 as a tumor suppressor: it binds cell-cycle–related mRNAs and drives the degradation of *TUBB4B* mRNA, a tubulin gene that fuels CRC proliferation when left unchecked. Restoring TUBB4B reversed PNLDC1's suppressive effect, marking the tubulin as the actionable node.

That is where mebendazole comes in: as a TUBB4B inhibitor, it effectively suppressed the enhanced proliferation of low-PNLDC1 tumors across all three model systems. The abstract reports no effect sizes (no IC50 or tumor-volume figures), so the magnitude of the benefit remains to be quantified — and PNLDC1 status would need to prove itself as a biomarker. This is mechanism-level evidence, not a clinical signal; for how benzimidazoles are actually being used and discussed, see our [dosing calculator](https://www.sanarelab.science/protocol-dosing-workspace/), the [fenbendazole vs mebendazole comparison](https://www.sanarelab.science/fenbendazole-vs-mebendazole-cancer/) and the [wider mebendazole mechanism research](https://www.sanarelab.science/mebendazole-reprograms-oncogenic-networks-multi-cancer-2026/).

## References

1. Liu L, Guan Y, Qin Y, et al. ER-Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B. *Exploration*. 2026 Sep 21\. [doi:10.1002/exp2.70222](https://doi.org/10.1002/exp2.70222?ref=sanarelab.science). [PMID: 42774471](https://pubmed.ncbi.nlm.nih.gov/42774471/?ref=sanarelab.science).

## Medical Disclaimer

This article is for informational purposes only and is not medical advice. The study described is preclinical research in laboratory models, not a trial in patients. Never start, stop or change any medication without consulting a licensed healthcare provider.